Skip to main content
Caplight Logo









Iktos

Iktos

Private
ParisHealthcare & Life Scienceshttps://iktos.ai/

Last Round

Grant

Feb 20, 2025

Total Funding Raised

$22.02M

Company Overview

Iktos is a biotechnology company that utilizes artificial intelligence and robotics platforms to accelerate the drug discovery and development process.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Medical AI, ML Platforms, Biotechnology, Industrial Robotics

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Revenue Share

AI Layer

Application

Keywords

AI drug discoverygenerative AIsmall molecule discoveryde novo drug designdrug discovery platformcomputer-aided drug designCADDAI retrosynthesisin silico drug designautomated synthesislab automationdesign-make-test-analyzeDMTAdrug discovery SaaSpharma techdrug discovery servicessynthesis planningdrug discovery pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Iktos Comparables

Compare Iktos with similar companies based on industry and business-model similarity.

Iktos comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TandemAI
86%
PostEra
84%
Aqemia
83%

Iktos Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 20, 2025
Series AMar 9, 2023
SeedJan 1, 2019
SeedJul 5, 2018

Key People

Founding team and executive leadership

Nicolas Do Huu

Founder, Chief Technology Officer

Founding Team

Fabien Guillemot

CFO

Executive Team

Iktos Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 13, 2026

    Multi-year agreement with Servier Group, potentially exceeding €1 billion.

  • Feb 20, 2025

    Secured $2.61M in grant funding.

Iktos Filings

Explore SEC and related filing metadata, where available.

Iktos filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Iktos's valuation, stock price, and market status.

Is Iktos a public or private company?

Iktos is a private company.

What is the current stock price of Iktos?

Iktos is a private company with no public stock price. No recent secondary market data is available.

How much is Iktos worth (valuation)?

Valuation information for Iktos is not publicly available.

Can I buy Iktos stock?

Iktos shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Iktos's last funding round?

Iktos's most recent funding round was Grant on February 20, 2025.

Who are the main investors in Iktos?

Key investors in Iktos include M Ventures.

Will Iktos IPO soon?

No public IPO plans have been announced for Iktos.

How can I track Iktos secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Iktos's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range60
Year Founded2016
Last FundingFeb 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?